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ABSTRACT 33 
Background: Sustained β-adrenergic receptor (β-AR) stimulation causes pathophysiologic changes 34 
during heart failure (HF), including inhibition of the slow component of the delayed rectifier current, IKs. 35 
Aberrant calcium handling, including increased activation of calcium/calmodulin-dependent protein 36 
kinase II (CaMKII), contributes to arrhythmia development during HF.   37 
Objective: To investigate CaMKII regulation of KCNQ1 (pore-forming subunit of IKs) during sustained 38 
β-AR stimulation and associated functional implications on IKs. 39 
Methods: KCNQ1 phosphorylation was assessed using LCMS/MS following sustained β-AR 40 
stimulation with isoproterenol (ISO). Peptide fragments corresponding to KCNQ1 residues were 41 
synthesized to identify CaMKII phosphorylation at the identified sites. Dephosphorylated (alanine) and 42 
phosphorylated (aspartic acid) mimics were introduced at identified residues.  Whole-cell, voltage-43 
clamp experiments were performed in HEK 293 cells co-expressing wild-type (WT) or mutant KCNQ1 44 
and KCNE1 (auxiliary subunit) during ISO treatment or lentiviral δCaMKII overexpression.     45 
Results: Novel KCNQ1 carboxyl terminus sites were identified with enhanced phosphorylation during 46 
sustained β-AR stimulation at T482 and S484. S484 peptides demonstrated the strongest δCaMKII 47 
phosphorylation. Sustained β-AR stimulation reduced IKs activation (p=0.02 versus control) similar to 48 
phosphorylated mimic (p=0.62 versus sustained β-AR).  Individual phosphorylated mimics at S484 49 
(p=0.04) but not T482 (p=0.17) reduced IKs function. Treatment with CN21 (CaMKII inhibitor)  50 
reversed the reductions in IKs versus CN21-Alanine control (p<0.01). δCaMKII overexpression reduced 51 
IKs similar to ISO treatment in WT (p<0.01) but not in the dephosphorylated S484 mimic (p=0.99).  52 
Conclusion: CaMKII regulates KCNQ1 at S484 during sustained β-AR stimulation to inhibit IKs. The 53 
ability of CaMKII to inhibit IKs may contribute to arrhythmogenicity during HF. 54 
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INTRODUCTION55 
Sustained elevations in beta-adrenergic receptor (β-AR) stimulation, a hallmark pathophysiologic 56 
finding in heart failure (HF), prolong the cardiac action potential and thereby increase the risk for 57 
ventricular arrhythmogenesis and sudden cardiac death.  Past investigations have demonstrated 58 
functional deficits in repolarizing potassium currents during HF, including those in the slow component 59 
of the delayed rectifier potassium current, IKs.1-560 
IKs is mediated by interaction of the pore-forming subunit, KCNQ1, with the auxiliary subunit, 61 
KCNE1.  During acute or intermittent β-AR stimulation, IKs function is enhanced via KCNQ1 62 
phosphorylation by a protein kinase A (PKA)-dependent signaling complex to stabilize cardiac 63 
conduction during rapid heart rates.6  Although acute β-AR signaling enhances IKs function to stabilize 64 
cardiac conduction, sustained β-AR stimulation has been suggested to pathologically inhibit IKs 65 
function.2, 7  Functional reductions in IKs have been demonstrated to prolong action potential duration 66 
(APD) and increase arrhythmogenesis in both HF models and in patients carrying Long QT Phenotype 1 67 
(LQT1) mutations in the KCNQ1 gene.8, 9  68 
Several investigations have characterized mechanisms by which LQT1 mutations disrupt IKs 69 
function. In particular, the intracellular carboxy terminus of KCNQ1 (residues 352-676) has been shown 70 
to be involved in channel gating, membrane trafficking, interaction with KCNE1, and subunit 71 
tetramerization.10-12 Though previous investigations have elucidated the functional significance of 72 
various regions of the KCNQ1 carboxy terminal, the potential for changes in carboxy terminal 73 
phosphorylation in response to sustained β-AR stimulation, and the associated functional impact on IKs, 74 
have not been well characterized.   75 
Calcium/calmodulin-dependent protein kinase II (CaMKII) has been demonstrated to 76 
pathologically regulate many ion channels, including cardiac potassium channels, resulting in prolonged 77 
APD and increased arrhythmia development.13  In particular, CaMKII has been established as a mediator 78 
of arrhythmogenesis during sustained β-AR stimulation and HF, wherein the expression and activity of 79 
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CaMKII are increased.14 The objective of this study was to assess the potential for CaMKII to regulate 80 
IKs during sustained β-AR stimulation via KCNQ1 phosphorylation.  81 
82 
METHODS83 
Cell Culture84 
Human endothelial kidney (HEK 293) cells were purchased from ATCC® and maintained in Modified 85 
Essential Medium with 10% Fetal Bovine Serum and 1% Pen-Strep (5,000 Units/mL Penicillin; 5,000 86 
µg/mL Streptomycin) at 37°C and 5% CO2. To achieve β-AR stimulation, isoproterenol 100 nM (ISO; 87 
β1, β2-adrenergic receptor agonist) was added directly to culture media. IKs responsiveness to 88 
stimulation of endogenous β-ARs has been previously demonstrated in HEK 293 cells.15  The following 89 
reagents were commercially purchased: ISO (Sigma-Aldrich®); myristolated PKI (EMD Millipore®); 90 
tat-CN21, CN21, tat-CN21-Alanine, CN21-Alanine (Biopeptide Co.,Inc.®); KN-92, KN-93 (Santa Cruz 91 
Biotech®). 92 
93 
cDNA Transfection 94 
Complementary DNA encoding for human (h) KCNQ1 and hKCNE1 in pCDNA3.1 were used. Point 95 
mutations to alanine (A) and aspartic acid (D) were generated in hKCNQ1 by site-directed mutagenesis. 96 
hKCNQ1 (WT and mutants), hKCNE1, and enhanced green fluorescent protein (GFP) were co-97 
transfected using Lipofectamine 2000 (ThermoFisher®) at the ratio: 750 ng KCNE1, 500 ng KCNQ1, 98 
100 ng GFP. 99 
100 
CaMKII Protein Immunoblot 101 
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Protein was loaded and run on 10% SDS-polyacrylamide gel, transferred to PVDF membranes 102 
(ThermoFisher®), and blocked with 5% BSA in TBST.  Membranes were exposed to primary CaMKII 103 
(1:1000, Boster Biological Technology®) or CaMKII P287 (1:1000, Novus Biologicals®) antibodies, 104 
primary GAPDH (1:2000, Santa Cruz Biotech®) and secondary anti-mouse (1:5000, Santa Cruz 105 
Biotech®) antibodies, and developed using Pierce ECL Western Blotting Substrate (ThermoFisher®) and 106 
a Chemi-Doc Imager (Bio-Rad®).  107 
108 
Viral Transduction 109 
Constitutively active human δCaMKII was inserted into a packaging plasmid with an amino terminal 110 
fused yellow fluorescent protein (YFP) tag.  The packaging plasmid (20 µg) was co-transfected into 111 
HEK 293T cells along with viral gene plasmids [pRRE (10 µg), pRSV-Rev (5 µg), pCMV-VSV-G (6 112 
µg)] using polyethylenimine (50 µg) in Opti-MEM (ThermoFisher®). Cells were maintained in virus-113 
containing filtered media (0.45 µm) along with polybrene (Sigma-Aldrich®; 8 µg: 1 mL viral media) for 114 
6 hours.  Effective transduction was confirmed by YFP expression at 2 days following infection. 115 
116 
Mass Spectrometry117 
HEK293 cells expressing hKCNQ1 / hKCNE1 were incubated with ISO 100 nM. Cells were lysed and 118 
enriched membrane preparations (100 µg) were reduced, alkylated and digested with trypsin.16 Digested 119 
samples were analyzed using a Thermo-Finnigan linear ion-trap (LTQ) mass spectrometer coupled with 120 
a Surveyor autosampler and MS HPLC system (ThermoFinnigan®). The complete LCMS/MS methods 121 
have been previously described in detail.16  Only proteins and peptides with protein probability ≥ 0.9000 122 
and peptide probability ≥ 0.8000 are reported.  Protein quantification was performed using a label-free 123 
quantification software package, IdentiQuantXLTM.17  124 
125 
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Electrophysiology126 
Functional measurements were assessed using the whole-cell, patch-clamp configuration in the voltage-127 
clamp mode at room temperature (~22°C).  ISO and inhibitors were incubated in culture media and 128 
replaced with external (bath) solution during experiments that did not contain ISO. Activation currents 129 
were measured using a voltage step protocol using an EPC-9 amplifier and PatchMaster software 130 
(HEKA Elektronik®). The sampling rate was set to 20,000 samples/second.  The voltage dependence of 131 
activation was assessed in elicited tail currents when the voltage returned to -40 mV after the activating 132 
steps.  The internal patch solution was composed of (mM): K-Aspartate 110, KCl 20, MgCl2•6H2O 1, 133 
HEPES 10, Mg-ATP 5, EGTA 5, while the external patch solution was composed of (mM): NaCl 140, 134 
KCl 5.4, NaH2PO4 0.33, CaCl2•2H2O 1.8, MgCl2•6H2O 1, HEPES 5, Glucose 10.  The internal solution 135 
was adjusted to a pH of 7.2 using KOH, and the external solution was adjusted to a pH of 7.4 using 136 
NaOH.  Pipettes were pulled from borosilicate glass using a P-2000 Puller (Sutter Instrument®) with 137 
resistances of 2-7 MΩ. The mean measured liquid junctional potential for all experimental groups was 138 
14.2±2.7 mV. Reported values were not corrected for the liquid junction potential. Series resistance 139 
compensation was not performed. The average cell capacitance was 18.6±0.4 (mean±SEM) pF and the 140 
average series resistance was 18.1±0.5 MΩ.  141 
142 
KCNQ1 Peptide Array 143 
Immobilized peptides were synthesized on a modified cellulose membrane using a robotic peptide 144 
synthesizer (Intavis MultiPep®) with routine Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry as 145 
previously described.18, 19 Human δCaMKII (10 nM) was activated with Ca2+/CaM and Mg-ATP before 146 
the autophosphorylated kinase plus Mg-[γ-32P]ATP was added to the membrane, as described.18    In 147 
conditions evaluating peptide selectivity by PKA, catalytic subunit (10 nM) from bovine heart (Sigma 148 
#P2645) was added along with Mg-ATP (10 mM/0.1mM) and Mg-[γ-32P]ATP to label substrates, as 149 
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described for CaMKII. Phosphorylated peptides were visualized with a phosphoimager (Fuji®) and 150 
quantified using MultiGauge® (Version 3.0).  151 
152 
Data Analysis 153 
Analysis was performed using FitMaster (Version 2x73.1; HEKA®) and GraphPad Prism (Version 154 
6.03).  A Boltzmann distribution was used to fit normalized activation curves with the equation:  155 
(Eq. 1) I/Imax = 1/ (1+exp[(V1/2-V)/k]).  156 
where I/Imax is the normalized current, V is membrane voltage, V1/2 is the voltage of half-maximal 157 
activation, and k is the slope factor. Mono-exponential curves were fit to activation and tail currents to 158 
estimate rate constants of activation and deactivation at voltages that elicited measurable channel 159 
activation (0 to +60 mV). Protein abundance, phospho-stimulated luminescence, peak activation current 160 
density, V1/2, and rate constants were compared via one-way ANOVA with Tukey’s HSD post-hoc test 161 
or independent sample t-test with Welch correction.  All data are expressed as mean±standard error of 162 
the mean (SEM) and alpha set to 0.05. 163 
164 
RESULTS165 
The KCNQ1 carboxy terminus is differentially phosphorylated during sustained β-AR stimulation 166 
Basal phosphorylation of KCNQ1 was identified on five residues on the carboxy terminus (Figure 1A). 167 
The phosphorylation status at T482, S484, and S457 was decreased in the presence of KCNE1 co-168 
transfection (Supplemental Figure 1). Phosphorylation was enhanced at S407, T482, S484, and T624, 169 
(p<0.02) following sustained 4-hour ISO treatment in the presence of KCNE1. The increased 170 
phosphorylation was maintained following sustained 24-hour treatment at T482 (p<0.01) and S484 171 
(p=0.01).   172 
Sustained β-AR stimulation pathologically activates CaMKII which is an important mediator of 173 
arrhythmogenesis.20 Therefore, the ability of activated δCaMKII to phosphorylate intracellular regions 174 
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of KCNQ1 was assessed using a peptide array.  Luminescent signals corresponding to CaMKII 175 
phosphorylation were visible on peptides containing T482 and S484 (Figure 1B; complete peptide 176 
sequences in Supplemental Table 1). ScanSite3 (http://scansite3.mit.edu/#home) predicted S457 and 177 
S484 as sites of CaMKII phosphorylation.  Therefore, residues S457, T482, and S484, which reside 178 
within the region connecting calmodulin-binding domains in KCNQ1 helices A and B, were assessed for 179 
CaMKII-mediated regulation (Figure 1C).  180 
181 
Sustained β-AR stimulation inhibits IKs  182 
The impact of sustained β-AR stimulation on IKs function was assessed following treatment with 100 nM 183 
ISO for 12-24 hours. IKs function was similar following 4-6 hour and 12-24 hour ISO treatment 184 
(Supplemental Figure 2). As displayed in Figure 2A/B, sustained ISO treatment reduced peak 185 
corrected currents at +60 mV (voltage of maximum activation) from 45.6±7.9 pA/pF (n=20) to 21.5±4.0 186 
(n=14), p=0.01.  ISO treatment also resulted in a depolarizing shift in the voltage dependence of 187 
activation with a V1/2 of 20.6±0.8, n=19 with vehicle vs. 26.1±0.8 mV, n=12 following ISO treatment, 188 
p<0.01; Figure 2C and Supplemental Table 2.  Rate constants were not statistically different (Figures 189 
2D and 2E). 190 
191 
Phosphorylation at S457, T482, and S484 in combination inhibit IKs activation currents192 
The functional implications of phosphorylation at the identified residues were investigated in HEK 293 193 
cells co-expressing KCNE1 and KCNQ1 mutants conferring mimics of dephosphorylation (A) or 194 
phosphorylation (D) at S457, T482, and S484 in combination: triple-alanine KCNQ1 (Triple-A; 195 
dephosphorylated mimic) and triple-aspartic acid KCNQ1 (Triple-D; phosphorylated mimic).  As 196 
displayed in Figure 2G, Triple-A mutants increased mean peak corrected activation currents (50.0±8.7 197 
pA/pF, n=10 at +60 mV) relative to Triple-D mutants (24.5±4.2, n=13, p=0.02). Sustained treatment 198 
with ISO did not decrease IKs with Triple-A (50.0±8.7, n=10 with vehicle vs. 70.5±13.3, n=18 following 199 
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ISO, p=0.21) or Triple-D mutants (24.5±4.2, n=13 with vehicle vs. 32.9±5.1, n=13 following ISO, 200 
p=0.22).  The V1/2 was not different between Triple-A and Triple-D mutants (19.5±0.9 mV, n=10 vs. 201 
20.2±1.1, n=13, respectively; p=0.66), and sustained ISO treatment did not alter V1/2 in Triple-A 202 
(19.5±0.9, n=10 with vehicle vs. 22.3±0.6, n=18 following ISO, p=0.25) or Triple-D mutants (V1/2 of 203 
20.2±1.1 mV, n=13 with vehicle vs. 19.2±0.6, n=12 following ISO, p=0.44; Figure 2H).  Rate constants 204 
of activation or deactivation were not different between mutants (Figure 2I and 2J). Relative to Triple-205 
A, Triple-D mutants demonstrate reduced IKs currents similar to WT with sustained ISO (Figure 2K).  206 
207 
Phosphorylation at S457 and S484, but not at T482, inhibit IKs208 
Mimics of dephosphorylation (A) or phosphorylation (D) were individually introduced at S457, T482, 209 
and S484. IKs activation was decreased with S457D KCNQ1 relative to S457A with a mean of 70.7±12.3 210 
(n=16) in S457A and 40.4±4.1 pA/pF (n=19) in S457D at +60 mV, p=0.02; (V1/2 of 28.6±2.5 mV, n=15 211 
for S457D vs. 21.6±1.7, n=12 for S457A, p=0.03) Figure 3A. Conversely, IKs activation current density 212 
were not different between T482 mimics (64.3±11.4, n=22 in T482D vs. 73.8±11.3, n=22 in T482A at 213 
+60 mV, p=0.53 and V1/2 of 24.8±4.2 mV, n=14 for T482D vs. 24.7±2.2, n=16 for T482A, p=0.99;214 
Figure 3B).  Mimics of phosphorylation at S484 decreased IKs current density and right shifted the 215 
voltage dependence of activation relative to dephosphorylation mimics (61.9±10.8, n=20 in S484D vs. 216 
100.4±13.7, n=22 in S484A at +60 mV, p=0.04 and V1/2 of 28.3±3.1 mV, n=15 for S484D vs. 19.6±1.8, 217 
n=11 for S484A, p=0.02; Figure 3C). Reduced IKs function with S484D versus S484A was only 218 
observed during co-expression with KCNE1 (Figure 3C). KCNQ1-related current was not different 219 
between S484A and S484D in the absence of KCNE1 expression (Supplemental Figure 3). 220 
221 
CaMKII mediates functional inhibition of IKs during sustained β-AR stimulation222 
IKs currents were assessed during sustained ISO and co-treatment with the CaMKII peptide inhibitor 223 
CN21 or its inactive analogue, CN21-Alanine (10 µM tat-CN21 or tat-CN21-Ala in culture media for 4 224 
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hours and 1 µM CN-21 or CN21-Ala in pipette solution ). CN21 reversed sustained ISO induced 225 
reductions in IKs activation (71.9±5.1 pA/pF, n=10 with CN21 vs. 47.2±5.9, n=12 with CN21-Ala, 226 
p<0.01; Figure 4A/B).  The sustained ISO induced depolarizing shift in the voltage dependence of 227 
activation was reversed with CN21 (V1/2 of 13.8±1.3 mV, n=6 with CN21 vs. 20.2±2.1, n=6 with CN21-228 
Ala, p<0.01; Figure 4C).  Co-incubation with the PKA peptide inhibitor myristoylated-PKI (1 µM in 229 
culture media for 4 hours and in pipette solution) did not attenuate ISO-induced changes in IKs (Figure 230 
4A-C). The chemical CaMKII inhibitor KN-93 also attenuated ISO-induced changes in IKs relative to 231 
KN-92 control (Supplemental Figure 4C-E).   232 
CaMKII activity was assessed following sustained ISO treatment via phosphorylation at T287, a 233 
residue at which CaMKII is autophosphorylated to confer constitutive kinase activity.21  T287 234 
phosphorylation relative to GAPDH was increased by 36.8% during ISO treatment versus control 235 
(p<0.05) while CaMKII expression relative to GAPDH was not changed following ISO treatment; 236 
p=0.62 (Figure 4D).   237 
238 
CaMKII inhibits IKs through phosphorylation at S484 239 
A peptide array was used to assess site-specific δCaMKII phosphorylation of the KCNQ1 carboxy 240 
terminal residues identified by LCMS/MS.  The strongest δCaMKII phosphorylation signals were 241 
detected in peptides containing T482 and S484 (Figure 5).  By individually mutating T482 or S484 to 242 
alanine, strong phosphorylation signals were detected in all peptide fragments containing WT S484, 243 
including the T482KO (Spot 3). Peptides containing the T482 residue as the lone potential 244 
phosphorylation site (S484A, Spot 5) displayed negligible signals relative to peptides containing S484 245 
alone (40.7± 1.9 for S484A vs. 1605.3±67.8 for the T482KO, p<0.01).  Peptides containing S407, S457, 246 
T482, S484, and T624 were not phosphorylated when exposed to activated PKA (<2.5% of positive 247 
control signal, Supplemental Figure 5). Peptide sequences are defined in Supplemental Table 3, and 248 
the full membranes displayed in Supplemental Figure 6. 249 
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The potential for CaMKII to mediate IKs function at S484 and/or S457 was assessed in a HEK 250 
293 cell line that stably overexpressed YFP-tagged constitutively active δCaMKII (T287D) and 251 
transiently co-expressed WT or mutant KCNQ1 with KCNE1.  A lentiviral plasmid containing YFP was 252 
stably expressed as control.  As shown in Figure 6A/B, IKs current density was inhibited during CaMKII 253 
overexpression relative to control (67.3±9.3 pA/pF, n=15 in control vs. 35.8±5.8, n=15 in CaMKII at 254 
+60 mV, p=0.01). The CaMKII induced IKs inhibition observed in WT KCNQ1 was reversed with255 
S484A (60.9±9.1, n=10 for S484A mutants in CaMKII vs. 35.8±5.8, n=15 for WT KCNQ1 in CaMKII, 256 
p=0.04) but not S457A (35.6±7.0, n=10 for S457A in CaMKII vs. 35.8±5.8, n=15 for WT KCNQ1 in 257 
CaMKII, p=0.99).  Relative to lentiviral control, CaMKII induced a depolarizing shift in the voltage 258 
dependence of activation similar to that of sustained ISO (V1/2 of 18.5±1.4 mV, n=11 in control vs. 259 
22.2±0.8, n=11 in CaMKII, p=0.03; Figure 6C).  Rate constants of activation were not different (Figure 260 
6D), however, rate constants of deactivation were reduced in cells expressing WT KCNQ1 relative to 261 
S484A with CaMKII (Figure 6E). 262 
263 
DISCUSSION264 
In contrast to enhancement during acute stimulation, sustained β-AR stimulation reduces IKs 265 
function by an unclear mechanism.6, 7 Although functional deficits in IKs contribute to an increased risk 266 
of ventricular arrhythmias, the regulation of IKs during sustained β-AR stimulation is poorly defined. In 267 
this study, we identified a CaMKII-dependent reduction in IKs current density during sustained β-AR 268 
stimulation through phosphorylation at a residue (S484) in the region connecting two alpha-helical 269 
calmodulin-binding domains on KCNQ1.  270 
CaMKII is a serine/threonine kinase known to pathologically regulate ion channel function and 271 
excitation-contraction coupling in cardiomyocytes during HF.20  Furthermore, CaMKII mediates 272 
arrhythmia development in a vast range of cardiac diseases, including HF, through aberrant calcium 273 
handling.14, 22, 23  Through regulation of cardiac ion channels, including the repolarizing potassium 274 
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channels Ito and IK1, CaMKII facilitates increases in both action potential duration and arrhythmogenic 275 
propensity in HF models.24, 25  While CaMKII regulation of IKs has not previously been established, 276 
investigations of LQT1 mutants in the KCNQ1 carboxy terminus demonstrate a necessary role for 277 
calmodulin in IKs function.10, 26  278 
The KCNQ1 carboxy terminus is required for proper channel co-assembly, trafficking, and 279 
regulation.10-12 Therefore, post-translational modifications in the KCNQ1 carboxy terminus could have 280 
profound effects on IKs.  While there is a paucity of data investigating the functional effects of site-281 
specific phosphorylation, LQT1 mutations in carboxy terminal domains have been investigated.  For 282 
example, helix A mutations (R366W, A371T, S373P, and W392R) disrupt calmodulin binding and 283 
reduce IKs function by altering channel assembly, stabilizing inactivation, and decreasing current 284 
density.26  In the current study, the reduction of IKs via CaMKII occurred through phosphorylation at 285 
S484, a residue in the region connecting the calmodulin-binding domains in helices A (residues 370-286 
389) and B (residues 506-532). Interestingly, the co-expression of KCNE1 with KCNQ1 reduced basal287 
phosphorylation at S484 versus KCNQ1 alone. Additionally, phosphorylation and dephosporylation 288 
mimics did not alter KCNQ1-related current in the absence of KCNE1. Together, these results suggest 289 
that reductions in IKs may involve alterations in KCNQ1 and auxiliary subunit interactions through 290 
phosphorylation but further mechanistic information is needed.  291 
Aflaki et al. assessed the regulation of IKs during sustained β-AR stimulation in a guinea pig 292 
model.7  In accordance with our results, IKs was inhibited in response to ISO treatment for 30 hours.  293 
Additionally, they demonstrated a role for the exchange protein activated by cyclic-AMP (Epac) 294 
pathway in mediating IKs during sustained β-AR stimulation. Since CaMKII is enhanced downstream of 295 
Epac activation, it is not surprising that functional reductions in IKs were reversed with CaMKII 296 
inhibition during sustained β-AR stimulation.27, 28 Therefore, the findings from Aflaki et al. support the 297 
current findings that CaMKII regulates IKs during sustained β-AR stimulation.   298 
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In this study, the significance of the S484 residue was demonstrated by alanine substitutions that 299 
reversed the effects of CaMKII which was further supported by peptide array and biochemical data.  A 300 
potential limitation of this approach is that basal phosphorylation exists on the identified residues. 301 
Therefore, it is not surprising that alanine substitutions (S484A, S4857A, and T482A alone and in 302 
combination) trended, albeit non-significantly, toward a current density increase versus WT. Aspartic 303 
acid is also not a perfect mimic of phosphorylation and, therefore, the assessment of WT versus D 304 
substitutions may not represent the full effect of phosphorylation. Additional limitations include those 305 
associated with the cellular model which lack the precise control of cell surface expression. Given 306 
potential variability between experiments, controls were assessed during the time of each experimental 307 
group and the ratio of KCNQ1 to KCNE1 was standardized to produce classical characteristics of IKs.  308 
309 
CONCLUSIONS 310 
In summary, in response to sustained β-AR stimulation, CaMKII phosphorylates KCNQ1 at 311 
S484 to inhibit IKs function.  Inhibition of IKs activation is consistent with the depolarizing shifts in the 312 
voltage dependence of activation during ISO treatment and CaMKII overexpression. It is also consistent 313 
with decreases in deactivation rate constants observed during CaMKII overexpression. These functional 314 
findings are consistent with our proteomic and biochemical analyses, which demonstrate that 315 
phosphorylation at S484 is enhanced during sustained β-AR stimulation and that S484 is a specific site 316 
of CaMKII phosphorylation. This study expands on previous findings to propose a molecular 317 
understanding of how CaMKII regulates IKs function during sustained β-AR stimulation. The potential 318 
for CaMKII to inhibit IKs during sustained β-AR stimulation may contribute to arrhythmogenicity during 319 
HF. Future investigations are warranted to assess the pathophysiological role of S484 regulation via 320 
CaMKII in cardiac tissue. 321 
322 
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Figure Legends 323 
Figure 1 324 
(A) Phosphorylation status of KCNQ1 carboxy terminus in HEK 293 cells (co-expressing KCNQ1 and325 
KCNE1) following treatment with 100 nM ISO for 3 minutes, 4 hours, and 24 hours via LCMS/MS 326 
analysis.  (B) Peptide fragments corresponding to the intracellular regions of KCNQ1 were exposed to 327 
activated δCaMKII for 4 minutes and 30 seconds. Each peptide was 15 amino acids in length, tiled by 328 
two residues for 13 overlapping residues per consecutive peptide. Peptide fragments containing residues 329 
T482 and S484 (solid box at D5-D7) were the strongest substrates for CaMKII phosphorylation. The 330 
dashed box at D5-D7 is following 30 second exposure of activated δCaMKII. The solid box (F15-F19) 331 
contains a autocamtide-2 negative control (TA mutation; F15), WT autocamtide-2 positive control 332 
(F17), and kemptide control (classical PKA substrate; F19). Full peptide sequences are in Supplemental 333 
Table 1. (C) Schematic of KCNQ1 and KCNE1 subunits showing carboxy terminal sites of potential 334 
CaMKII regulation investigated. *p<0.05 vs. control335 
336 
Figure 2 337 
(A) Representative traces of I
Ks
 activation currents from WT KCNQ1/KCNE1 following 100 nM ISO or338 
vehicle for 12-24 hours. (B) I-V plots, (C) activation curves (normalized to the voltage of maximum 339 
activation), and (D) rate constants of activation and (E) deactivation following treatment with ISO or 340 
vehicle. (F) Representative traces of I
Ks
 from KCNQ1 combination mimics of dephosphorylation341 
(Triple-A) and phosphorylation (Triple-D) co-expressed with KCNE1. (G) I-V plots, (H) activation 342 
curves, and (I) rate constants of activation and (J) deactivation for Triple-A and Triple-D KCNQ1. (K) 343 
Peak current density at +60 mV for WT KCNQ1 and combination mimics following ISO or vehicle. 344 
*p<0.05 vs. WT+ISO, 
+
p<0.05 for Triple-A vs. Triple-D, 
ǂ
p<0.05 for Triple-A+ISO vs. Triple-D+ISO, 345 
**p<0.05 for comparison indicated 346 
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347 
Figure 3 348 
(A) I-V plots, peak current density, and activation curves for WT, S457A, and S457D KCNQ1/KCNE1349 
(B) I-V plots, peak current density, and activation curves for WT, T482A, and T482D KCNQ1/KCNE1.350 
(C) I-V plots, peak current density, and activation curves for WT, S484A, and S484D KCNQ1/KCNE1.351 
*p<0.05352 
Figure 4 353 
(A) I-V plots and (B) peak current density for WT KCNQ1/KCNE1 following treatment with ISO (100354 
nM for 12-24 hours) and CN21, CN21-Ala, or myr-PKI. (C) Normalized activation curves following 355 
ISO with CN21, CN21-Ala, or myr-PKI. (D) Immunoblots and percent changes in CaMKII and CaMKII 356 
T287 phosphorylation following 100 nM ISO for 24 hours. *p<0.05 357 
358 
Figure 5 359 
(A) KCNQ1 carboxy peptides were exposed to activated δCaMKII. Each row contains peptides360 
corresponding to the labeled KCNQ1 residue with columns for WT, A (phospho-acceptor site mutated 361 
to alanine), or KO (all serine and threonine mutated to alanine with the exception of T482 wherein S484 362 
was not mutated; n=5 for each condition). (B) Quantification of phosphostimulated luminescence for 363 
WT, A, and KO peptides corresponding to KCNQ1 T482 and S484 during exposure to activated 364 
δCaMKII. *p<0.05, ns = not significant 365 
366 
Figure 6 367 
(A) I-V plots and (B) peak current density  for WT or mutant KCNQ1 co-expressed with KCNE1 in368 
cells overexpressing constitutively active δCaMKII or YFP control. (C) Normalized activation curves 369 
for WT KCNQ1 when expressed in CaMKII overexpression and control. (D) Rate constants of 370 
activation and (E) deactivation for WT KCNQ1 and S484A during CaMKII overexpression. 
+
p<0.05 for 371 
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Control, WT vs. CaMKII, WT, 
ǂ
p<0.05 for CaMKII, S484A vs. CaMKII, WT, **p<0.05 for comparison 372 
indicated, *p<0.05 for CaMKII, WT vs. CaMKII, S484A 373 
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